Cerliponase alfa 24 month review – Summary
Cerliponase alfa 24 month review – consumer version
About this resource
Publication date:
Publication type:
Report
Audience:
General public
Language:
English
Australian Government Department of Health, Disability and Ageing
Cerliponase alfa 24 month review
This review aimed to undertake an assessment after 24 months listing on the LSDP to ensure that the listing of cerliponase alfa for the treatment of CLN2 disease remains appropriate. This review was considered by the Expert Panel at its October 2021 meeting.